Meropenem-vaborbactam

Revision as of 23:12, 22 September 2019 by ClaireLewis (talk | contribs) (→‎References)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Carbapenem+beta lactamase inhibitor
  • Dosage Forms: 2 gram (1 gram each) solution reconstituted
  • Routes of Administration: IV
  • Common Trade Names: Vabomere

Adult Dosing

Complicated UTI (including pyelonephritis)

  • 4 g IV q8h (administered over 3 hours)

Pediatric Dosing

Special Populations

Pregnancy Rating

Unknown

Lactation risk

  • Meropenem is present in breast milk

Renal Dosing

  • eGFR >50: none
  • eGFR 30 to 49: 2 g q8h
  • eGFR 15 to 29: 2 g q12h
  • eGFR <15: 1 g q12h
  • ESRD on HD: Administer after HD on dialysis days

Hepatic Dosing

None

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • DVT (<1%)
  • Increased risk of seizures

Common

  • Phlebitis
  • Headache
  • Hypokalemia
  • Diarrhea
  • Increased ALT/AST
  • Infusion site reaction

Pharmacology

  • Half-life: Meropenem 1.2 hours; Vaborbactam 1.68 hours
  • Metabolism:
  • Excretion: Meropenem (urine); Vaborbactam (urine)

Mechanism of Action

  • Meropenem inhibits bacterial cell wall synthesis
  • Vaborbactam is a beta-lactamase inhibitor that protects meropenem from degradation by KPC

Comments

  • Cost: 1 g: ~$200

See Also

References

Retrieved from "https://www.wikem.org/w/index.php?title=Meropenem-vaborbactam&oldid=229504"